TEXTOTEX CYP 250 -Testosterone Cypionate

Key Benefits of TEXTOTEX CYP 250: Fundamental hormonal base: Testosterone is the primary anabolic hormone of the human body and the foundation of any cycle. It provides the androgenicity needed to maintain physiological function while maximizing results . Documented muscle mass gains: A recent clinical study (2024) demonstrated that testosterone cypionate therapy significantly increases fat-free mass and reduces total fat mass . Studies confirm injectable testosterone is more potent for lean muscle mass gains than transdermal formulations . Improved physical performance: 2026 research shows testosterone significantly improves strength, power, and peak aerobic performance (VO2 peak) . Improved stair-climbing power and peak aerobic performance have been documented with testosterone cypionate therapy . Accelerated recovery: Promotes protein synthesis and nitrogen retention, reducing recovery time between workouts . Prolonged release: Cypionate ester has a 2-3 week duration of action, allowing weekly or biweekly administration with stable hormone levels . Metabolic efficacy: Testosterone improves nutrient utilization, reduces adipogenesis, and promotes myogenesis through PRDM16 signaling . Reduced expression of adipogenic markers (PPAR gamma) and increased myogenic markers (MYOD, PAX7, FOLLISTATIN) have been documented during testosterone cypionate therapy . Versatility: Effective as a base in bulking, cutting, and body recomposition cycles. Can be stacked with virtually any other anabolic compound. Established safety profile: Testosterone is the best-studied anabolic steroid, with well-documented safety profiles

How does TEXTOTEX CYP 250 work? Textotex CYP 250 contains Testosterone Cypionate USP, a long-acting testosterone ester administered intramuscularly. Testosterone cypionate should not be used interchangeably with testosterone propionate due to differences in duration of action . Protein synthesis: Testosterone binds to the androgen receptor, activating signaling pathways that promote protein synthesis and nitrogen retention, creating an anabolic state favorable for muscle growth . PRDM16 and adipo-myogenic switch: Recent research (2024-2025) has demonstrated that testosterone cypionate therapy significantly increases PRDM16 expression, a factor that regulates the shift from the adipogenic to myogenic pathway. This explains the reduction in body fat and increase in lean mass observed during testosterone therapy . Reduction of adipogenic markers: A significant reduction in PPAR gamma expression in subcutaneous fat and ADIPSIN in serum has been documented during testosterone therapy . Increase in myogenic markers: A concomitant increase in MYOD expression in peripheral blood mononuclear cells and PAX7 and FOLLISTATIN in serum has been observed during testosterone cypionate therapy . Aromatization: Testosterone is partially aromatized to estradiol. Recent research suggests that the increase in estradiol during testosterone therapy may at least partially mediate the shift from adipogenesis to myogenesis . Prolonged release: The cypionate ester is slowly released from the injection site, providing sustained testosterone release. The suggested dosage for replacement in the hypogonadal male is 50-400 mg every two to four weeks . Pharmacokinetics: Testosterone cypionate is a sterile oily solution for intramuscular administration. It presents as a clear, pale yellow solution

Usage Guide for TEXTOTEX CYP 250: Administration route: Deep and slow intramuscular injection, preferably in the glute (upper outer quadrant). Should not be administered intravenously . Frequency: Due to its prolonged-release action, administration is recommended every 7-14 days to maintain stable plasma levels. For athletic purposes, weekly administration is common . Recommended dosage for men: 250 to 750 mg per week (1 to 3 ampoules of TEXTOTEX CYP 250). In high-performance protocols, doses may be higher. The dosage for replacement in hypogonadal males is 50-400 mg every two to four weeks . In bodybuilding cycles, doses may range from 500-1000 mg/week . Recommended dosage for women: Testosterone use in women is not recommended due to high risk of virilization. Documented use in female athletes has resulted in doping sanctions . Recommended cycle: Ideal as a hormonal base in any bulking, cutting, or body recomposition cycle. Typical cycles of 8 to 16 weeks . Stacking: Testosterone is the base of virtually any cycle. It is frequently combined with other compounds such as nandrolone, boldenone, trenbolone, or oral compounds to enhance specific effects . Post-cycle therapy (PCT): PCT should be started approximately 2-3 weeks after the last injection due to the compound's prolonged release . Precautions and monitoring: Periodic monitoring of lipid profile, liver function, blood pressure, and hematocrit levels is recommended during the cycle . In diabetic patients, androgens may decrease blood glucose and, therefore, insulin requirements . Anti-doping warning: Testosterone is included in the WADA 2025-2026 Prohibited List as S1.1 Anabolic Androgenic Steroids, prohibited at all times (in and out of competition). WADA has clarified that esters of prohibited anabolic agents, such as testosterone cypionate, are also prohibited . A documented 2025 case shows an athlete sanctioned for two years for testosterone cypionate use

Composition of TEXTOTEX CYP 250: Active Ingredient: Testosterone Cypionate USP 250 mg per mL. High-purity compound with USP pharmaceutical grade . Chemical name: 17β-hydroxyandrost-4-en-3-one cyclopentanepropionate . Molecular formula: C₂₇H₄₀O₃ . Vehicle: Pharmaceutical-grade cottonseed oil . Preservative: Benzyl alcohol (approximately 9.45 mg/mL) as a bacteriostatic agent . Cosolvent: Benzyl benzoate (0.2 mL per mL) to improve solubility . Presentation: 1 mL ampoules with 250 mg/mL concentration (10 ampoules per box). Total of 250 mg of Testosterone Cypionate per ampoule. Appearance: Clear pale yellow oily solution . Classification: Schedule III controlled substance in the United States . Certification: Manufactured under USP (United States Pharmacopeia) and GMP (Good Manufacturing Practices) standards . Quality control: Purity and potency testing performed by certified independent laboratories using high-performance liquid chromatography (HPLC) and mass spectrometry. Purity: >98% purity, guaranteeing maximum quality and consistency in each batch. Storage: Store at controlled room temperature 20°-25°C (68°-77°F) [USP Controlled Room Temperature], in a dry place protected from light. Do not freeze. Warming and shaking the vial should redissolve any crystals that may have formed during storage at temperatures lower than recommended

Onset time and expected results: Onset time: Anabolic effects begin to be noticeable between 7 and 14 days of continuous use. Peak blood concentration is reached several hours after injection. Results at 2-4 weeks: Increased strength, improved recovery, increased libido, and general sense of well-being. Initial body weight increase. Results at 4-6 weeks: Significant improvement in body composition, lean muscle mass gain, and body fat reduction. Studies confirm documented fat-free mass gains . Results at 6-8 weeks: Notable muscle growth, sustained strength increase, and improved physical performance. Improved VO2 peak documented in clinical studies . Results at 8-12 weeks: Optimal results with quality muscle mass gains, increased strength, and superior physical performance. Expected results (10-12 week cycle at 500 mg/week): Lean muscle mass: Significant increase documented in clinical studies Total body mass: Body weight increase Strength increase in compound exercises: +10-20% Body fat reduction: Documented reduction in total and truncal fat mass Peak aerobic performance (VO2 peak): Documented improvement Recovery: Significantly accelerated

Clinical research and laboratory testing: SPIRIT Study 2026 (JAMA Internal Medicine): A randomized, double-blind, placebo-controlled study in 125 men demonstrated that testosterone cypionate (100 mg weekly for 12 weeks) significantly improved sexual activity, sexual desire, physical function, stair-climbing power, and peak aerobic performance (VO2 peak) compared to placebo. There was no biochemical prostate cancer recurrence during treatment or the three-month follow-up period . PRDM16 Study 2024 (Frontiers in Endocrinology): A study of 105 men (40-74 years) with late-onset hypogonadism who received testosterone cypionate 200 mg every 2 weeks for 18 months demonstrated a significant increase in fat-free mass and reduction in fat mass. The study identified that increased PRDM16 signaling, likely mediated by increased estradiol, regulates the shift from the adipogenic to myogenic pathway . Systematic Review 2025: A systematic review comparing the efficacy of injectable versus transdermal testosterone in increasing lean muscle mass in adult men with low testosterone concluded that injectable testosterone (enanthate/cypionate) demonstrated greater potency and superior absolute gains, attributed to its supraphysiological serum peaks . Medical applications: Testosterone cypionate is indicated for: Replacement therapy in hypogonadal males with confirmed testosterone deficiency by blood tests Under investigation for improving physical and sexual function in men after radical prostatectomy for low-grade prostate cancer Safety profile: Abuse of anabolic-androgenic steroids such as testosterone can lead to serious health risks, including cardiovascular, hepatic, and/or psychiatric effects . Documented side effects include: Lipid profile changes and increased hematocrit Gynecomastia due to aromatization HPG axis suppression In diabetic patients, androgens may decrease blood glucose and insulin requirements Documented doping cases: A documented 2025 case shows weightlifter Tiffany Hoffner sanctioned with two years of ineligibility for testosterone cypionate use, declared during sample collection at the 2025 USA Weightlifting Masters Nationals. The athlete did not have a valid Therapeutic Use Exemption (TUE) . 3rd party testing: Our batches are subjected to purity and potency testing by certified independent laboratories using: High-performance liquid chromatography (HPLC) for purity Mass spectrometry for molecular identification Sterility and bacterial endotoxin testing Certifications: Manufactured under GMP (Good Manufacturing Practices) standards USP quality control (United States Pharmacopeia) Stability and shelf-life testing (24 months) Heavy metals and contaminant analysis Anti-doping warning: Testosterone is included in the WADA 2025-2026 Prohibited List as S1.1 Anabolic Androgenic Steroids, prohibited at all times (in and out of competition). WADA has clarified that esters of prohibited anabolic agents, including testosterone cypionate, are also prohibited